Press Releases

- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc.
Dec 13, 2021
Displaying 1 - 10 of 22